When Arvinas reported Q2 2026 results showing revenue of US$249.7 million and net income of US$169.4 million, with net margin shifting from a heavy loss a year earlier to 67.8%, the headline story looked transformed. For Arvinas shareholders, the loss from the start of the year was 36.3%, including dividends. If you had been weighing a position back on 1 January, how should this kind of swing in reported performance have shaped your expectations?
Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.
The easy part of this move is behind Arvinas. Zero in on 29 high quality undervalued stocks for companies trading below our estimates.
The Two Arvinas Stories Investors Had In Front Of Them
The shares cost US$11.86 at the start of the period, and anyone looking at Arvinas then had to choose between two very different but plausible stories.
The bullish narrative put Fair Value at US$17.44, based on the idea that precision therapies and the PROTAC platform could support a profit margin assumption of 23.3% and a future P/E of 51.9x despite an assumed revenue decline of 25.2%.
The bearish view anchored Fair Value at US$7, focusing on heavy reliance on a narrow pipeline and milestone revenue, with revenue growth assumed to fall 49.7% and profitability only reaching a 20.9% margin on a future P/E of 76.3x.
What The Results Changed For The Arvinas Narratives
The biggest new fact was Arvinas reporting Q2 2026 revenue of US$249.7 million and net income of US$169.4 million, with net margin moving from a heavy loss of 273.2% in Q2 2025 to a 67.8% profit. That kind of profitability supported the bullish assumption that margins could improve. However, the earlier expectation of declining sales means this single quarter cut both ways rather than settling the argument.
The clear hinge here was the margin assumption. When you assess another biotech, track how net margin and absolute profit line up against the story you were told about eventual profitability, not just the direction of revenue.
What Arvinas' Share Price Slide Already Assumes
Arvinas now trades at US$7.31, and this Narrative’s Fair Value sits above that level based on its own assumptions rather than any proven reality. The story leans on licensing, VEPPANU, and early degraders to justify why a weaker year to date share price might not fully reflect the pipeline.
A buyer today would need to believe that partnered deals and early data from programs like ARV‑102 and ARV‑027 can translate into future, clinically meaningful milestones while Arvinas maintains its reset cost base and cash runway. That is what would have to hold for the fall to look like opportunity rather than warning.
"Some analysts suggest that Arvinas could aim to turn its refocused early-stage PROTAC pipeline and disciplined partnering model into a broader revenue base that builds on the first approved degrader VEPPANU and the recent out licensing and milestone flows. For that to happen, Arvinas would need to convert early signals in programs like ARV‑102, ARV‑027, ARV‑393 and ARV‑6723 into clinically meaningful data while staying within its reset cost structure and cash runway into the second half of 2028."
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all
Another Way To Frame Arvinas
Arvinas points you toward targeted biology. One step away sits a different kind of drug engine.
Instead of degraders, this business leans on hormone and metabolic treatments that reshape how chronic conditions are managed.
Its recent focus is on weight loss and diabetes medicines that can change patient behavior by making treatment easier to start and maintain.
Alongside that, a class of injectable and oral therapies is moving through late trials, aimed at problems ranging from sleep disorders to heart risk.
If Arvinas is your lesson in early science risk, this peer raises a separate question about investing around a pipeline already woven into daily care.
The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 15% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com